{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:01Z","timestamp":1791908281836,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SWARD Abu Dhabi UAE","award":["SWARD-F22-370 013) awarded on August 30"],"award-info":[{"award-number":["SWARD-F22-370 013) awarded on August 30"]}]},{"name":"SWARD Abu Dhabi UAE","award":["2022 to Riad Bayoumi."],"award-info":[{"award-number":["2022 to Riad Bayoumi."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) and metabolic dysfunction\u2013associated steatotic liver disease (MASLD), which have a reciprocal relationship compounded by obesity, are highly prevalent in the Middle East affecting morbidity, mortality, and healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the severity of MASLD and liver fibrosis among adult Emirati patients with long-standing T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Participants<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study used noninvasive methods to assess the severity of MASLD and fibrosis progression in an adult cohort of Emirati patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009546) with a mean T2DM duration of 16\u00a0years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>\n                      Fatty liver infiltration was assessed by hepatic steatosis index (HSI), while fibrosis was assessed by the fibrosis-4 (FIB-4) index and aspartate aminotransferase\/platelet ratio index (APRI). Of those, 108 patients were randomly subjected to ultrasound-based FibroScan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      to assess controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      All patients had fatty liver with\u2009~\u200983% being categorized as having severe steatosis. Serum-based fibrosis biomarker panels detected significant liver fibrosis in\u2009~\u20092.5% of these patients. The APRI appeared to be more restrictive in detecting moderate fibrosis (1.5%) than the FIB-4 index (25.5%). CAP significantly correlated with the LSM, indicating that the two methods contributed to the same underlying pathophysiology. Liver steatosis was more severe in female patients, who were older and had a higher body mass index (BMI) than those with moderate or no significant fibrosis. They also had higher serum liver enzymes and were more likely to have age-related changes in kidney function. Interestingly, severity of both steatosis and fibrosis remained unaffected by age and duration of T2D except for fibrosis severity detected by FibroScan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the critical need for routine screening of MASLD among Emirati patients with long-standing T2DM, given the high point prevalence of severe steatosis (~\u200983%), predominantly among women in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-09348-2","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T10:03:15Z","timestamp":1737540195000},"page":"2309-2318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes"],"prefix":"10.1007","volume":"40","author":[{"given":"Farooq","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-6930","authenticated-orcid":false,"given":"Stafny","family":"Dsouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-3066","authenticated-orcid":false,"given":"Amar Hassan","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-5640","authenticated-orcid":false,"given":"Fatima","family":"Abdul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-3715","authenticated-orcid":false,"given":"Muhammad Hamed","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-4156","authenticated-orcid":false,"given":"Fatima","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0017-8339","authenticated-orcid":false,"given":"Fahad","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-866X","authenticated-orcid":false,"given":"Fatheya","family":"Al Awadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-6972","authenticated-orcid":false,"given":"Mohammed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-8129","authenticated-orcid":false,"given":"Riad","family":"Bayoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"9348_CR1","doi-asserted-by":"publisher","unstructured":"Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. Clin Liver Dis (Hoboken). 2012;1(4). https:\/\/doi.org\/10.1002\/cld.81.","DOI":"10.1002\/cld.81"},{"key":"9348_CR2","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4). https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"9348_CR3","doi-asserted-by":"publisher","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9). https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"9348_CR4","doi-asserted-by":"publisher","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction\u2013associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. Published online November 9, 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000670.","DOI":"10.1097\/HEP.0000000000000670"},{"key":"9348_CR5","doi-asserted-by":"publisher","unstructured":"Rinella ME, Lazarus J V., Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6). https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"9348_CR6","doi-asserted-by":"publisher","unstructured":"Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36). https:\/\/doi.org\/10.3748\/wjg.v23.i36.6571.","DOI":"10.3748\/wjg.v23.i36.6571"},{"key":"9348_CR7","doi-asserted-by":"publisher","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1). https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","DOI":"10.1038\/nrgastro.2017.109"},{"key":"9348_CR8","doi-asserted-by":"publisher","unstructured":"Ratziu V, Boursier J, de Ledinghen V, Anty R, Costentin C, Bureau C. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2024;80(2). https:\/\/doi.org\/10.1016\/j.jhep.2023.07.017.","DOI":"10.1016\/j.jhep.2023.07.017"},{"key":"9348_CR9","doi-asserted-by":"publisher","unstructured":"Song SJ, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(2). https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","DOI":"10.1016\/j.jhep.2023.07.021"},{"key":"9348_CR10","doi-asserted-by":"publisher","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5). https:\/\/doi.org\/10.1097\/HEP.0000000000000670.","DOI":"10.1097\/HEP.0000000000000670"},{"key":"9348_CR11","doi-asserted-by":"publisher","unstructured":"Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes. 2021;12(9). https:\/\/doi.org\/10.4239\/wjd.v12.i9.1479.","DOI":"10.4239\/wjd.v12.i9.1479"},{"key":"9348_CR12","doi-asserted-by":"publisher","unstructured":"Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606. J Hepatol. 2020;73(3). https:\/\/doi.org\/10.1016\/j.jhep.2020.04.003.","DOI":"10.1016\/j.jhep.2020.04.003"},{"key":"9348_CR13","doi-asserted-by":"publisher","unstructured":"Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6). https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"9348_CR14","doi-asserted-by":"publisher","unstructured":"Ram\u00edrez-Mej\u00eda MM, Jim\u00e9nez-Guti\u00e9rrez C, Eslam M, George J, M\u00e9ndez-S\u00e1nchez N. Breaking new ground: MASLD vs. MAFLD\u2014which holds the key for risk stratification? Hepatol Int. 2024;18(1). https:\/\/doi.org\/10.1007\/s12072-023-10620-y.","DOI":"10.1007\/s12072-023-10620-y"},{"key":"9348_CR15","doi-asserted-by":"publisher","unstructured":"Aktas G. Serum C-reactive protein to albumin ratio as a reliable marker of diabetic neuropathy in type 2 diabetes mellitus. Biomol Biomed. 2024 Sep 6;24(5):1380\u20131386. https:\/\/doi.org\/10.17305\/bb.2024.10426.","DOI":"10.17305\/bb.2024.10426"},{"issue":"10","key":"9348_CR16","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/liv.13739","volume":"38","author":"LC Bertot","year":"2018","unstructured":"Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38(10):1793-1802. https:\/\/doi.org\/10.1111\/liv.13739.","journal-title":"Liver Int."},{"issue":"7","key":"9348_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069.","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-801. https:\/\/doi.org\/10.1172\/JCI29069.","journal-title":"J Clin Invest."},{"key":"9348_CR18","doi-asserted-by":"publisher","unstructured":"Barrera F, Uribe J, Olvares N, Huerta P, Cabrera D, Romero-G\u00f3mez M. The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease. Ann Hepatol. 2024;29(4). https:\/\/doi.org\/10.1016\/j.aohep.2024.101501.","DOI":"10.1016\/j.aohep.2024.101501"},{"key":"9348_CR19","doi-asserted-by":"publisher","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1). https:\/\/doi.org\/10.1186\/s12933-024-02434-5.","DOI":"10.1186\/s12933-024-02434-5"},{"key":"9348_CR20","doi-asserted-by":"publisher","unstructured":"Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-year prospective cohort study. Hepatology. 2013;57(4). https:\/\/doi.org\/10.1002\/hep.26183.","DOI":"10.1002\/hep.26183"},{"key":"9348_CR21","doi-asserted-by":"publisher","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6). https:\/\/doi.org\/10.1038\/nrgastro.2013.41.","DOI":"10.1038\/nrgastro.2013.41"},{"key":"9348_CR22","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rkstr\u00f6m K, St\u00e5l P, Hultcrantz R, Hagstr\u00f6m H. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15(9). https:\/\/doi.org\/10.1016\/j.cgh.2017.04.040.","DOI":"10.1016\/j.cgh.2017.04.040"},{"key":"9348_CR23","doi-asserted-by":"publisher","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care. 2018;41(2). https:\/\/doi.org\/10.2337\/dc17-1902.","DOI":"10.2337\/dc17-1902"},{"key":"9348_CR24","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4). https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"9348_CR25","doi-asserted-by":"publisher","unstructured":"Rhee EJ. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. Endocrinol Metab. 2019;34(3). https:\/\/doi.org\/10.3803\/EnM.2019.34.3.226.","DOI":"10.3803\/EnM.2019.34.3.226"},{"key":"9348_CR26","doi-asserted-by":"publisher","unstructured":"Stevens GA, Singh GM, Lu Y, et al. * for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). Popul Health Metr. 2012;10. https:\/\/doi.org\/10.1186\/1478-7954-10-22.","DOI":"10.1186\/1478-7954-10-22"},{"key":"9348_CR27","doi-asserted-by":"publisher","unstructured":"Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Front Nutr. 2022;9. https:\/\/doi.org\/10.3389\/fnut.2022.1047129.","DOI":"10.3389\/fnut.2022.1047129"},{"key":"9348_CR28","doi-asserted-by":"publisher","unstructured":"Alswat K, Aljumah AA, Sanai FM, et al. Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017\u20132030. Saudi J Gastroentero. 2018;24(4). https:\/\/doi.org\/10.4103\/sjg.SJG_122_18.","DOI":"10.4103\/sjg.SJG_122_18"},{"key":"9348_CR29","doi-asserted-by":"publisher","unstructured":"Wilson S, Chalasani N. Noninvasive Markers of Advanced Histology in Nonalcoholic Fatty Liver Disease: Are We There yet? Gastroenterology. 2007;133(4). https:\/\/doi.org\/10.1053\/j.gastro.2007.08.045.","DOI":"10.1053\/j.gastro.2007.08.045"},{"key":"9348_CR30","doi-asserted-by":"publisher","unstructured":"Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53(2). https:\/\/doi.org\/10.1007\/s00535-017-1414-2.","DOI":"10.1007\/s00535-017-1414-2"},{"key":"9348_CR31","doi-asserted-by":"publisher","unstructured":"Juo YY, Livingston EH. Testing for Nonalcoholic Fatty Liver Disease. JAMA J Am Med Assoc. 2019;322(18). https:\/\/doi.org\/10.1001\/jama.2019.10696.","DOI":"10.1001\/jama.2019.10696"},{"key":"9348_CR32","doi-asserted-by":"publisher","unstructured":"Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol. 2020;10(1). https:\/\/doi.org\/10.1016\/j.jceh.2019.09.006.","DOI":"10.1016\/j.jceh.2019.09.006"},{"key":"9348_CR33","doi-asserted-by":"publisher","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2). https:\/\/doi.org\/10.1016\/j.jhep.2023.08.026.","DOI":"10.1016\/j.jhep.2023.08.026"},{"key":"9348_CR34","doi-asserted-by":"publisher","unstructured":"Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7). https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","DOI":"10.1016\/j.dld.2009.08.002"},{"key":"9348_CR35","doi-asserted-by":"publisher","unstructured":"Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST\/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol. 2021;21(1). https:\/\/doi.org\/10.1186\/s12876-021-02038-3.","DOI":"10.1186\/s12876-021-02038-3"},{"key":"9348_CR36","doi-asserted-by":"publisher","unstructured":"Friedrich-Rust M, Ong MF, Martens S, et al. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. Gastroenterology. 2008;134(4). https:\/\/doi.org\/10.1053\/j.gastro.2008.01.034.","DOI":"10.1053\/j.gastro.2008.01.034"},{"key":"9348_CR37","doi-asserted-by":"publisher","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5). https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"9348_CR38","doi-asserted-by":"publisher","unstructured":"Ng CH, Chan KE, Chin YH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28(3). https:\/\/doi.org\/10.3350\/cmh.2022.0096.","DOI":"10.3350\/cmh.2022.0096"},{"key":"9348_CR39","doi-asserted-by":"publisher","unstructured":"Kalan Farmanfarma KH, Ansari-Moghaddam A, Zareban I, Adineh HA. Prevalence of type 2 diabetes in Middle\u2013East: Systematic review& meta-analysis. Prim Care Diabetes. 2020;14(4). https:\/\/doi.org\/10.1016\/j.pcd.2020.01.003.","DOI":"10.1016\/j.pcd.2020.01.003"},{"key":"9348_CR40","doi-asserted-by":"publisher","unstructured":"Feldman H, ElSayed NA, McCoy RG, et al. Standards of Care in Diabetes\u20142023 Abridged for Primary Care Providers. Clin Diabetes. 2023;41(1). https:\/\/doi.org\/10.2337\/cd23-as01.","DOI":"10.2337\/cd23-as01"},{"key":"9348_CR41","doi-asserted-by":"publisher","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6). https:\/\/doi.org\/10.1002\/hep.21178.","DOI":"10.1002\/hep.21178"},{"key":"9348_CR42","doi-asserted-by":"publisher","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2). https:\/\/doi.org\/10.1053\/jhep.2003.50346.","DOI":"10.1053\/jhep.2003.50346"},{"issue":"5","key":"9348_CR43","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010.","journal-title":"Endocr Pract."},{"issue":"1","key":"9348_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","volume":"18","author":"J Ampuero","year":"2020","unstructured":"Ampuero J, Pais R, Aller R, et al. Development and Validation of Hepamet Fibrosis Scoring System\u2013A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2020;18(1):216-225.e5. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.051.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"9348_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, Leiva EG, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care. 2021;44(2):399-406. https:\/\/doi.org\/10.2337\/dc20-1997.","journal-title":"Diabetes Care."},{"issue":"10","key":"9348_CR46","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-1112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9348_CR47","doi-asserted-by":"publisher","unstructured":"Alqahtani SA, Golabi P, Paik JM, et al. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg. 2021;31(5). https:\/\/doi.org\/10.1007\/s11695-020-04996-1.","DOI":"10.1007\/s11695-020-04996-1"},{"key":"9348_CR48","doi-asserted-by":"publisher","unstructured":"Arab JP, Barrera F, Arrese M. The evolving role of liver biopsy in non-alcoholic fatty liver disease. Ann Hepatol. 2018;17(6). https:\/\/doi.org\/10.5604\/01.3001.0012.7188.","DOI":"10.5604\/01.3001.0012.7188"},{"key":"9348_CR49","doi-asserted-by":"publisher","unstructured":"McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9). https:\/\/doi.org\/10.1136\/gut.2010.216077.","DOI":"10.1136\/gut.2010.216077"},{"key":"9348_CR50","doi-asserted-by":"publisher","unstructured":"Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: A systematic review. Ann Intern Med. 2013;158(11). https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00005.","DOI":"10.7326\/0003-4819-158-11-201306040-00005"},{"key":"9348_CR51","doi-asserted-by":"publisher","unstructured":"Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5). https:\/\/doi.org\/10.1002\/hep.29302.","DOI":"10.1002\/hep.29302"},{"key":"9348_CR52","doi-asserted-by":"publisher","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5). https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","DOI":"10.1053\/j.gastro.2018.12.036"},{"key":"9348_CR53","doi-asserted-by":"publisher","unstructured":"Petta S, Wong VWS, Camm\u00e0 C, et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther. 2017;46(6). https:\/\/doi.org\/10.1111\/apt.14219.","DOI":"10.1111\/apt.14219"},{"key":"9348_CR54","doi-asserted-by":"publisher","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9). https:\/\/doi.org\/10.1038\/s41575-021-00448-y.","DOI":"10.1038\/s41575-021-00448-y"},{"key":"9348_CR55","doi-asserted-by":"publisher","unstructured":"Joo SK, Kim W, Kim D, et al. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver International. 2018;38(2). https:\/\/doi.org\/10.1111\/liv.13549.","DOI":"10.1111\/liv.13549"},{"key":"9348_CR56","doi-asserted-by":"publisher","unstructured":"Durazzo M, Marzari L, BoNetto S, et al. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: Diagnostic accuracy of different scores. Minerva Gastroenterol Dietol. 2021;66(4). https:\/\/doi.org\/10.23736\/S1121-421X.20.02753-1.","DOI":"10.23736\/S1121-421X.20.02753-1"},{"key":"9348_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27844\/suppinfo","author":"S Petta","year":"2015","unstructured":"Petta S, Maida M, Macaluso FS, et al. The Severity of Steatosis Influences Liver Stiffness Measurement in Patients With Nonalcoholic Fatty Liver Disease. Published online 2015. https:\/\/doi.org\/10.1002\/hep.27844\/suppinfo.","journal-title":"Published online"},{"key":"9348_CR58","doi-asserted-by":"publisher","unstructured":"\u00d6nnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 2019;54(3). https:\/\/doi.org\/10.1080\/00365521.2019.1583366.","DOI":"10.1080\/00365521.2019.1583366"},{"key":"9348_CR59","doi-asserted-by":"publisher","unstructured":"Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431). https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2.","DOI":"10.1016\/S0140-6736(23)02750-2"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09348-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09348-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09348-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:16:42Z","timestamp":1755011802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09348-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9348"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09348-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests:"}},{"value":"The views expressed in the submitted article are our own and not an official position of the institution or funder.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer:"}}]}}